Literature DB >> 19239442

1H-nuclear magnetic resonance spectroscopy for identifying and quantifying common uropathogens: a metabolic approach to the urinary tract infection.

Ashish Gupta1, Mayank Dwivedi, Abbas Ali Mahdi, G A Nagana Gowda, Chunni Lal Khetrapal, Mahendra Bhandari.   

Abstract

OBJECTIVE: To address the shortcomings of urine culture for the diagnosis of urinary tract infection (UTI), we used 1H-nuclear magnetic resonance (NMR) spectroscopy for identifying and quantifying Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumonia and Proteus mirabilis. PATIENTS, SUBJECTS AND METHODS: Urine samples from patients with suspected UTI (617), healthy volunteers (50) and commercially available standard strains of E. coli, K. pneumonia, P. aeruginosa, Enterobacter, Acinobacter, Pr. mirabilis, Citrobacter frundii, Streptococcus saprophyticus and Enterococcus faecalis were assessed between 2003 and 2006. 1H-NMR spectra were recorded on a 400 MHz spectrophotometer; to quantify the bacteria we estimated the areas under the spectral peaks of the specific metabolic product compared with the known concentration of trimethyl silyl propionic acid. All urine specimens were cultured in addition to an assessment by NMR spectroscopy.
RESULTS: Preliminary urinary spectroscopy of the unprocessed samples showed peaks of nonspecific metabolites such as succinate, acetate, lactate and ethanol, indicating infected samples. Based on the results from processed samples, 93% (240/256) of E. coli, 92% (101/110) of K. pneumoniae, 93% (56/60) of P. aeruginosa and eight of 10 Pr. mirabilis could be diagnosed with NMR (numerator) and urine culture (denominator). The remaining samples were sterile and/or had a bacterial population of <10(3) colony-forming units (CFU)/mL. The NMR method diagnosed bacterial densities of >10(3) CFU.
CONCLUSIONS: The identification of the common uropathogens E. coli, K. pneumoniae, P. aeruginosa and Pr. mirabilis by NMR spectroscopy has a shorter reporting time and can be used to differentiate between infected, contaminated and sterile specimens.

Entities:  

Mesh:

Year:  2009        PMID: 19239442     DOI: 10.1111/j.1464-410X.2009.08448.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Proton Nuclear Magnetic Resonance Spectroscopy as a Technique for Gentamicin Drug Susceptibility Studies with Escherichia coli ATCC 25922.

Authors:  Lara García-Álvarez; Jesús H Busto; Alberto Avenoza; Yolanda Sáenz; Jesús Manuel Peregrina; José A Oteo
Journal:  J Clin Microbiol       Date:  2015-05-13       Impact factor: 5.948

2.  Inhibition of adherence of multi-drug resistant E. coli by proanthocyanidin.

Authors:  Ashish Gupta; Mayank Dwivedi; Abbas Ali Mahdi; G A Nagana Gowda; Chunni Lal Khetrapal; Mahendra Bhandari
Journal:  Urol Res       Date:  2011-06-19

3.  1H NMR spectroscopy-based metabolomics analysis for the diagnosis of symptomatic E. coli-associated urinary tract infection (UTI).

Authors:  Milena Lussu; Tania Camboni; Cristina Piras; Corrado Serra; Francesco Del Carratore; Julian Griffin; Luigi Atzori; Aldo Manzin
Journal:  BMC Microbiol       Date:  2017-09-21       Impact factor: 3.605

Review 4.  Diagnostic Applications of Nuclear Magnetic Resonance-Based Urinary Metabolomics.

Authors:  Ana Capati; Omkar B Ijare; Tedros Bezabeh
Journal:  Magn Reson Insights       Date:  2017-03-07

Review 5.  Metabolomic-Based Methods in Diagnosis and Monitoring Infection Progression.

Authors:  Miguel Fernández-García; David Rojo; Fernanda Rey-Stolle; Antonia García; Coral Barbas
Journal:  Exp Suppl       Date:  2018

6.  (1)H NMR-based metabolic profiling of urinary tract infection: combining multiple statistical models and clinical data.

Authors:  Ekaterina Nevedomskaya; Tiziana Pacchiarotta; Artem Artemov; Axel Meissner; Cees van Nieuwkoop; Jaap T van Dissel; Oleg A Mayboroda; André M Deelder
Journal:  Metabolomics       Date:  2012-02-29       Impact factor: 4.290

Review 7.  Metabonomics and intensive care.

Authors:  David Antcliffe; Anthony C Gordon
Journal:  Crit Care       Date:  2016-03-16       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.